Superficial and nodular basal cell carcinomas treated with an immune response modifier: A report of seven patients

Clinical and Experimental Dermatology, Supplement

Volumn 28, Issue 1, 2003, Pages 24-26

  Bianchi, L ^a   Costanzo, A ^a   Campione, E ^a   Nistico S ^a   Chimenti, S ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; AMINOQUINOLINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; EROSION; ERYTHEMA; FEMALE; HUMAN; MALE; PREVALENCE; PRIORITY JOURNAL; SCAR FORMATION; SIDE EFFECT; SKIN CANCER; TREATMENT INDICATION; CASE REPORT; CLINICAL FEATURE; IMMUNE RESPONSE; SUPERFICIAL CANCER; MIDDLE AGED; OINTMENT; SKIN TUMOR; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ADULT; AGED; AMINOQUINOLINES; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 1842586450     PISSN: 09663487     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.28.s1.8.x     Document Type: Article

References (13)

1. Goldberg LH. Basal cell carcinoma. Lancet 1996; 347: 663-7.
2. McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma: a possible indicator of differing causes. Arch Dermatol 1997; 133: 593-6.
3. Cornell RC, Greenway HT, Tucker SB et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990; 23: 694-700.
4. Drake LA, Ceilley RI, Cornelison RL et al. Guidelines for the care of basal cell carcinoma. J Am Acad Dermatol 1992; 26: 117-20.
5. Beutner KR, Geisse JR, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-7.
6. Marks R, Gebauer K, Shumack S et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-13.
7. Drehs MM, Cook-Bolden F, Tanzi EL, Weinberg JM. Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature. Dermatol Surg 2002; 28: 427-9.
8. Chen TM, Rosen T, Orengo I. Treatment of a large superficial basal cell carcinoma with 5% imiquimod cream: a case report and review of the literature. Dermatol Surg 2002; 28: 344-6.
9. Geisse JK, Rich P, Pandya A et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47: 390-8.
10. Shumack S, Robinson J, Kossard S et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Arch Dermatol 2002; 138: 1165-71.
11. Sterry W, Ruzicka T, Herrera E et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomised studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147: 1227-36.
12. Salasche S. Imiquimod 5% cream: a new treatment option for basal cell carcinoma. Int J Dermatol 2002; 41: 16-20.
13. Bianchi L, Francesconi F, Carboni I, Barbati R, Chimenti S. Imiquimod 5% cream in the treatment of basal cell carcinoma. Poster presented at the 20th World Congress of Dermatology. Paris, France, 2002.